Radius Health (RDUS) Reports Narrower Q4 Loss Than Expected
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Radius Health (RDUS) PT Lifted to $56 at Jefferies; Potentially Early Efficacy Data for RAD1901 at ASCO
March 11, 2015 7:35 AM EDTJefferies analyst Eun K. Yang reiterated a Buy rating and lifted the price target on Radius Health (NASDAQ: RDUS) to $56.00 (from $45.00) following in-line Q4 results but potentially early efficacy data for RAD1901 at ASCO.
Yang commented, "With positive, clean Ph3 data for... More
